Protein Fibril Length in Cerebrospinal Fluid is Increased in Alzheimer's Disease

Overview

Journal Commun Biol

Specialty Biology

Date 2023 Mar 8

PMID 36890343

Authors

Peter Niraj Nirmalraj

Thomas Schneider

Lars Luder

Ansgar Felbecker

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) associated proteins exist in cerebrospinal fluid (CSF). This paper evidences that protein aggregate morphology distinctly differs in CSF of patients with AD dementia (ADD), mild cognitive impairment due to AD (MCI AD), with subjective cognitive decline without amyloid pathology (SCD) and with non-AD MCI using liquid-based atomic force microscopy (AFM). Spherical-shaped particles and nodular-shaped protofibrils were present in the CSF of SCD patients, whereas CSF of ADD patients abundantly contained elongated mature fibrils. Quantitative analysis of AFM topographs confirms fibril length is higher in CSF of ADD than in MCI AD and lowest in SCD and non-AD dementia patients. CSF fibril length is inversely correlated with CSF amyloid beta (Aβ) 42/40 ratio and CSF p-tau protein levels (obtained from biochemical assays) to predict amyloid and tau pathology with an accuracy of 94% and 82%, respectively, thus identifying ultralong protein fibrils in CSF as a possible signature of AD pathology.

Citing Articles

3D Holo-tomographic Mapping of COVID-19 Microclots in Blood to Assess Disease Severity.

Bergaglio T, Synhaivska O, Nirmalraj P Chem Biomed Imaging. 2024; 2(3):194-204.

PMID: 39474148 PMC: 11503935. DOI: 10.1021/cbmi.3c00126.

Accelerated Alzheimer's Aβ-42 secondary nucleation chronologically visualized on fibril surfaces.

Nirmalraj P, Bhattacharya S, Thompson D Sci Adv. 2024; 10(43):eadp5059.

PMID: 39454002 PMC: 11506133. DOI: 10.1126/sciadv.adp5059.

Exploring the Aβ fibrillogenesis timeline by atomic force microscopy and surface enhanced Raman spectroscopy.

Polykretis P, DAndrea C, Banchelli M, Napolitano L, Cascella R, de Angelis M Front Mol Biosci. 2024; 11:1376411.

PMID: 38948077 PMC: 11211275. DOI: 10.3389/fmolb.2024.1376411.

Protein fibril aggregation on red blood cells: a potential biomarker to distinguish neurodegenerative diseases from healthy aging.

Schneider T, Stockli L, Felbecker A, Nirmalraj P Brain Commun. 2024; 6(3):fcae180.

PMID: 38873003 PMC: 11170662. DOI: 10.1093/braincomms/fcae180.

References

Pitschke M, Prior R, Haupt M, Riesner D . Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med. 1998; 4(7):832-4. DOI: 10.1038/nm0798-832. View

Nirmalraj P, List J, Battacharya S, Howe G, Xu L, Thompson D . Complete aggregation pathway of amyloid β (1-40) and (1-42) resolved on an atomically clean interface. Sci Adv. 2020; 6(15):eaaz6014. PMC: 7141833. DOI: 10.1126/sciadv.aaz6014. View

Holtta M, Hansson O, Andreasson U, Hertze J, Minthon L, Nagga K . Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. PLoS One. 2013; 8(6):e66381. PMC: 3682966. DOI: 10.1371/journal.pone.0066381. View

Anoop A, Singh P, Jacob R, Maji S . CSF Biomarkers for Alzheimer's Disease Diagnosis. Int J Alzheimers Dis. 2010; 2010. PMC: 2915796. DOI: 10.4061/2010/606802. View

Aksnes M, Tiiman A, Edwin T, Terenius L, Bogdanovic N, Vukojevic V . Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimer's Disease. Front Aging Neurosci. 2021; 12:608628. PMC: 7820807. DOI: 10.3389/fnagi.2020.608628. View

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B . Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001; 58(3):373-9. DOI: 10.1001/archneur.58.3.373. View

Hansson O . Biomarkers for neurodegenerative diseases. Nat Med. 2021; 27(6):954-963. DOI: 10.1038/s41591-021-01382-x. View

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K . Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. JAMA Neurol. 2017; 74(12):1492-1501. PMC: 5822196. DOI: 10.1001/jamaneurol.2017.2814. View

10.

Bitan G, Kirkitadze M, Lomakin A, Vollers S, Benedek G, Teplow D . Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A. 2002; 100(1):330-5. PMC: 140968. DOI: 10.1073/pnas.222681699. View

11.

Nabers A, Perna L, Lange J, Mons U, Schartner J, Guldenhaupt J . Amyloid blood biomarker detects Alzheimer's disease. EMBO Mol Med. 2018; 10(5). PMC: 5938617. DOI: 10.15252/emmm.201708763. View

12.

Bader J, Geyer P, Muller J, Strauss M, Koch M, Leypoldt F . Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. Mol Syst Biol. 2020; 16(6):e9356. PMC: 7266499. DOI: 10.15252/msb.20199356. View

13.

Ruggeri F, Sneideris T, Vendruscolo M, Knowles T . Atomic force microscopy for single molecule characterisation of protein aggregation. Arch Biochem Biophys. 2019; 664:134-148. PMC: 6420408. DOI: 10.1016/j.abb.2019.02.001. View

14.

Stockmann J, Verberk I, Timmesfeld N, Denz R, Budde B, Lange-Leifhelm J . Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. Alzheimers Res Ther. 2020; 12(1):169. PMC: 7761044. DOI: 10.1186/s13195-020-00738-8. View

15.

Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B . Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999; 56(6):673-80. DOI: 10.1001/archneur.56.6.673. View

16.

Wattmo C, Blennow K, Hansson O . Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease. BMC Neurol. 2020; 20(1):10. PMC: 6951013. DOI: 10.1186/s12883-019-1591-0. View

17.

Rodriguez J, Karikari T, Suarez-Calvet M, Troakes C, King A, Emersic A . Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 2020; 140(3):267-278. PMC: 7423866. DOI: 10.1007/s00401-020-02195-x. View

18.

Blennow K, Hampel H, Weiner M, Zetterberg H . Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010; 6(3):131-44. DOI: 10.1038/nrneurol.2010.4. View

19.

Weissenberger G, Henderikx R, Peters P . Understanding the invisible hands of sample preparation for cryo-EM. Nat Methods. 2021; 18(5):463-471. DOI: 10.1038/s41592-021-01130-6. View

20.

Nirmalraj P, Schmid H, Gotsmann B, Riel H . Nanoscale origin of defects at metal/molecule engineered interfaces. Langmuir. 2013; 29(5):1340-5. DOI: 10.1021/la3046109. View